A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ho Wan-Ling, Hsieh Ming-Yun, Liao Yu-Mei, Chiou Shyh-Shin, Shiah Her-Shyong, Chiang Chang-Hsu, Jou Shiann-Tarng, Yen Hsiu-Ju, Lee Yi-Yen, Liang Muh-Lii, Yeh Ting-Chi, Chou Yu-Cheng, Huang Fang-Liang, Chen Shu-Huey, Lee Hsin-Lun, Kuo Chia-Chun, Yang Yi-Shan, Chen Shu-Mei, Tsai Min-Lan, Chang Hsi, Hsieh Kevin Li-Chun, Fang Chia-Lang, Chang Chia-Yau, Wang Jinn-Li, Chen Chu-Chin, Loh Joon-Khim, Lin Pei-Chin, Lin Tzu-Chin, Wang Shih-Chung, Tu Yi-Fang, Cheng Chao-Neng, Chuang Jimmy Ming-Jung, Tran Huy Minh, Sung Shian-Ying, Lai Irving, Wu Kuo-Sheng, Miser James S, Liu Yen-Lin, Wong Tai-Tong
Аннотация
METHODS: Six patients aged 0.8-13 years with newly diagnosed ATRT were enrolled from January 2022 through December 2023. Bortezomib was given intravenously at the dose of 1.3 mg/m2/day on days 1, 4, 8, and 11 of a 21-day chemotherapy cycle for 6 cycles. Radiation therapy was given before initiation of chemotherapy in 4 patients or at the end of chemotherapy in one patient. The primary endpoint was grade 3 or higher non-hematologic toxicities.
RESULTS: Thirty cycles of bortezomib with chemotherapy were evaluated. No grade 3 or higher toxicities were considered bortezomib-related. Four patients completed 6 cycles of bortezomib; 2 patients discontinued treatment due to progressive disease after 2 and 4 cycles, respectively. An additional 6 cycles of bortezomib were evaluated after high-dose chemotherapy in three patients without grade 4 bortezomib-related toxicity. Five patients had a near-total resection; one patient had a subtotal resection. Four patients were evaluable for response with 2 partial responses, 1 stable disease, and 1 progressive disease. Two patients without measurable tumor after surgery were not evaluable for response. Two patients remain alive without disease at 37 and 40 months, and one patient died without disease at 19 months after diagnosis. Three patients died with progressive disease.
CONCLUSIONS: The toxicities were no more than expected with chemotherapy alone. Adding bortezomib to treatment of ATRT is feasible.
TRIAL REGISTRATION: NCT06853080.